High Response Incidence Seen for Axatilimab in Recurrent, Refractory GVHD
Primary end point was met, with overall response for 74, 67, and 50 percent receiving axatilimab 0.3 mg, 1 mg, and 3 mg per kilogram of body weight
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.